A new clinical model for terminal idiopathic pulmonary fibrosis (IPF) that allows patients to receive treatment at home has increased patient satisfaction, decreased hospital deaths, led to better symptom management, and lowered healthcare costs. Those outcomes of this new clinical model were published recently in the journal NEJM…
News
The Pulmonary Fibrosis Foundation (PFF) announced that its nationwide Care Center Network (CCN) now encompasses 68 medical centers in 33 states, following the addition of eight sites with recognized expertise in pulmonary fibrosis (PF) diagnosis, treatment,…
A patient with idiopathic pulmonary fibrosis (IPF), enrolled in the ZEPHYRUS Phase 3 clinical study, has been dosed with FibroGen’s investigational therapy pamrevlumab, the company announced. Still recruiting participants, the ZEPHYRUS study (NCT03955146) is expected to enroll approximately 565 IPF patients who have not responded to,…
Increased activity of certain matrix metalloproteinases (MMPs), enzymes that regulate cell behavior, may explain the risk for developing aggressive pulmonary fibrosis in people with Hermansky-Pudlak syndrome (HPS), a rare genetic disorder, according to new research. The study highlights MMP-2 and MMP-9. The findings suggest that these unique…
Low levels of an enzyme associated with the rare childhood disorder sialidosis may lead to the development of idiopathic pulmonary fibrosis (IPF), according to new research. The findings also suggest that NEU1 enzyme levels may help in determining fibrosis’ risk and likely prognosis. The study “…
Boehringer Ingelheim will add Bridge Biotherapeutics’ experimental inhibitor BBT-877 to its portfolio of potential therapies for fibrosing interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF). This follows the completion of a collaboration and global license agreement between the two companies for the development of BBT-877 for…
The type 2 diabetes medication metformin suppresses the production of collagen, and induces a switch in lung fibroblasts that is associated with quickened recovery from fibrosis, according to a preclinical study. The findings support the use of this medication in patients with idiopathic pulmonary fibrosis (IPF). The research,…
The U.S. Food and Drug Administration (FDA) will allow the start of a Phase 2 clinical trial of treatment candidate GKT831 for idiopathic pulmonary fibrosis (IPF). GKT831 is an orally available inhibitor of the NOX1 and NOX4 enzymes, and has been explored for the treatment of liver and kidney…
A new international consortium based in Paris, and funded largely by the 28-member European Union, intends to speed the diagnosis of rare diseases, while also accelerating the development of treatments for the 95% of such illnesses that currently don’t have one. The European Joint Programme on Rare Diseases (EJP…
Patients older than 75 with idiopathic pulmonary fibrosis (IPF) are at higher risk of discontinuing treatment with Esbriet (pirfenidone) due to adverse reactions, namely anorexia, according to a retrospective analysis made in Japan. The study, “Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis,”…
